目的 研究参松养心胶囊联合盐酸伊伐布雷定片治疗慢性心力衰竭的临床疗效。方法 选取2017年6月-2019年12月在光山县人民医院治疗的84例慢性心力衰竭患者为研究对象，所有患者随机分为对照组和治疗组，每组各42例。对照组患者口服盐酸伊伐布雷定片，1片/次，2次/d。治疗组在对照组治疗的基础上口服参松养心胶囊，3粒/次，3次/d。两组患者持续治疗2周。观察两组患者临床疗效，比较两组的生活质量综合评定问卷（GQOLI-74）评分、明尼苏达心功能不全生活量表（MHLFQ）评分、6 min步行试验（6MWT）、心功能指标、血清学指标水平、血清炎性因子水平。结果 治疗后，治疗组总有效率为92.86%，显著高于对照组的84.33%（P<0.05）。治疗后，两组患者左心室收缩末期容积（LVESV）、左心室舒张末期内径（LVEDD）显著降低，左心室射血分数（LVEF）显著升高（P<0.05），且治疗组左心功能指标改善较多（P<0.05）。治疗后，两组患者MHLFQ评分显著降低，6MWT和GQOLI-74评分明显升高（P<0.05）；且治疗组改善较多（P<0.05）。治疗后，两组血清N末端B型钠尿肽原（NT-proBNP）和肌钙蛋白T（cTnT）水平显著降低（P<0.05）；并且治疗组血清NT-proBNP和cTnT水平降低较多（P<0.05）。治疗后，两组患血清白细胞介素（IL）-6、肿瘤坏死因子α（TNF-α）、超敏C反应蛋白（hs-CRP）水平显著降低（P<0.05）；并且治疗组血清炎性因子水平降低较多（P<0.05）。结论 参松养心胶囊联合盐酸伊伐布雷定片治疗慢性心力衰竭具有较好的疗效，能够改善患者心功能和生活质量，降低血清学指标和血清炎性因子水平，安全性较高，值得在临床上推广应用。

Objective To study the efficacy of Shensong Yangxin Capsules combined with Ivabradine Hydrochloride Tablets in treatment of chronic heart failure. Methods Patients (84 cases) with chronic heart failure in Guangshan People's Hospital from June 2017 to December 2019 were randomly divided into control and treatment groups, and each group had 42 cases. Patients in the control group were po administered with Ivabradine Hydrochloride Tablets, 1 tablet/time, twice daily. Patients in the treatment group were po administered with Shensong Yangxin Capsules on the basis of the control group, 3 grains/time, three times daily. Patients in two groups were treated for 2 weeks. After treatment, the clinical efficacies were evaluated, and GQOLI-74 score, MHLFQ score, 6MWT, cardiac function index, the serum level of serological index and inflammatory factors in two groups were compared. Results After treatment, the total effective rate of the treatment group was 92.86%, which was significantly higher than that of the control group (84.33%) (P<0.05). After treatment, the LVESV and LVEDD of the two groups were significantly decreased, but the LVEF of the two groups were significantly increased (P<0.05). And the indexes of left heart function in the treatment group were better than those in the control group (P<0.05). After treatment, the MHLFQ scores of the two groups were significantly decreased, but 6MWT and GQOLI-74 scores of the two groups were significantly increased (P<0.05). And the indexes in the treatment group were better than those in the control group (P<0.05). After treatment, the levels of NT-proBNP and cTnT in two groups were significantly decreased (P<0.05). And the levels of NT-proBNP and cTnT in the treatment group were significantly lower than those in the control group (P<0.05). After treatment, the serum levels of IL-6, TNF- and hs-CRP in two groups were significantly decreased (P<0.05). And the serum inflammatory factors in the treatment group were significantly lower than those in the control group (P<0.05). Conclusion Shensong Yangxin Capsules combined with Ivabradine Hydrochloride Tablets has clinical curative effect in treatment of chronic heart failure, can improve the cardiac function and quality of life of patients, reduce serological indexes and serum inflammatory factors, with good safety, which is worthy of clinical application.

R972